Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Galectin Therapeutics Inc...

    NASDAQ: GALT · Real-Time Price · USD
    3.24
    0.85 (35.56%)
    At close: Jun 18, 2025, 3:59 PM
    3.26
    0.62%
    After-hours: Jun 18, 2025, 07:59 PM EDT

    Galectin Therapeutics Statistics

    Share Statistics

    Galectin Therapeutics has 63.29M shares outstanding. The number of shares has increased by 0.26% in one year.

    Shares Outstanding

    n/a
    		 63.29M

    Shares Change (YoY)

    n/a
    		 0.26%

    Shares Change (QoQ)

    n/a
    		 0%

    Owned by Institutions (%)

    n/a
    		 16.18%

    Shares Floating

    n/a
    		 43.7M

    Failed to Deliver (FTD) Shares

    n/a
    		 127,684

    FTD / Avg. Volume

    n/a
    		 32.74%

    Short Selling Information

    The latest short interest is 8.9M, so 14.06% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 8.9M

    Short % of Shares Out

    n/a
    		 14.06%

    Short % of Float

    n/a
    		 23.6%

    Short Ratio (days to cover)

    n/a
    		 50.6

    Valuation Ratios

    The PE ratio is -1.71 and the forward PE ratio is -2.26. Galectin Therapeutics's PEG ratio is -0.63.

    PE Ratio

    n/a
    		 -1.71

    Forward PE

    n/a
    		 -2.26

    PS Ratio

    n/a
    		 0

    Forward PS

    n/a
    		 8.9

    PB Ratio

    n/a
    		 -0.78

    P/FCF Ratio

    n/a
    		 -1.92

    PEG Ratio

    n/a
    		 -0.63
    Financial Ratio History

    Enterprise Valuation

    Currently the Enterprise Value (EV) is not available for Galectin Therapeutics.

    EV / Sales

    n/a
    		 n/a

    EV / EBITDA

    n/a
    		 n/a

    EV / EBIT

    n/a
    		 n/a

    EV / FCF

    n/a
    		 n/a

    Financial Position

    The company has a current ratio of 0.49, with a Debt / Equity ratio of -1.03.

    Current Ratio

    n/a
    		 0.49

    Quick Ratio

    n/a
    		 0.49

    Debt / Equity

    n/a
    		 -1.03

    Debt / EBITDA

    n/a
    		 -2.56

    Debt / FCF

    n/a
    		 -2.54

    Interest Coverage

    n/a
    		 -7.66

    Financial Efficiency

    Return on Equity is n/a and Return on Invested Capital is n/a.

    Return on Equity

    n/a
    		 n/a

    Return on Assets

    n/a
    		 n/a

    Return on Invested Capital

    n/a
    		 n/a

    Revenue Per Employee

    n/a
    		 n/a

    Profits Per Employee

    n/a
    		 $-3,136,466.67

    Employee Count

    n/a
    		 15

    Asset Turnover

    n/a
    		 0

    Inventory Turnover

    n/a
    		 n/a

    Taxes

    Income Tax

    n/a
    		 n/a

    Effective Tax Rate

    n/a
    		 0%

    Stock Price Statistics

    The stock price has increased by 39.06% in the last 52 weeks. The beta is 0.55, so Galectin Therapeutics's price volatility has been higher than the market average.

    Beta

    n/a
    		 0.55

    52-Week Price Change

    n/a
    		 39.06%

    50-Day Moving Average

    n/a
    		 1.39

    200-Day Moving Average

    n/a
    		 1.85

    Relative Strength Index (RSI)

    n/a
    		 92.89

    Average Volume (20 Days)

    n/a
    		 389,950

    Income Statement

    Revenue

    n/a
    		 n/a

    Gross Profit

    n/a
    		 n/a

    Operating Income

    n/a
    		 -42.43M

    Net Income

    n/a
    		 -47.05M

    EBITDA

    n/a
    		 -41.47M

    EBIT

    n/a
    		 -41.51M

    Earnings Per Share (EPS)

    n/a
    		 -0.76
    Full Income Statement

    Balance Sheet

    The company has 15.12M in cash and 106.25M in debt, giving a net cash position of -91.13M.

    Cash & Cash Equivalents

    n/a
    		 15.12M

    Total Debt

    n/a
    		 106.25M

    Net Cash

    n/a
    		 -91.13M

    Retained Earnings

    n/a
    		 -401.57M

    Total Assets

    n/a
    		 9.53M

    Working Capital

    n/a
    		 -101.56M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -41.77M and capital expenditures 0, giving a free cash flow of -41.77M.

    Operating Cash Flow

    n/a
    		 -41.77M

    Capital Expenditures

    n/a
    		 n/a

    Free Cash Flow

    n/a
    		 -41.77M

    FCF Per Share

    n/a
    		 -0.67
    Full Cash Flow Statement

    Margins

    Gross Margin

    n/a
    		 n/a

    Operating Margin

    n/a
    		 n/a

    Pretax Margin

    n/a
    		 n/a

    Profit Margin

    n/a
    		 n/a

    EBITDA Margin

    n/a
    		 n/a

    EBIT Margin

    n/a
    		 n/a

    FCF Margin

    n/a
    		 n/a

    Dividends & Yields

    GALT does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 n/a

    FCF Yield

    n/a
    		 n/a
    Dividend Details

    Analyst Forecast

    The average price target for GALT is $6, which is 85.2% higher than the current price. The consensus rating is "Buy".

    Price Target

    n/a
    		 $6

    Price Target Difference

    n/a
    		 85.2%

    Analyst Consensus

    n/a
    		 Buy

    Analyst Count

    n/a
    		 1
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Stock Splits

    The last stock split was on Mar 23, 2012. It was a backward split with a ratio of 1:6.

    Last Split Date

    n/a
    		 Mar 23, 2012

    Split Type

    n/a
    		 backward

    Split Ratio

    n/a
    		 1:6

    Scores

    Altman Z-Score

    n/a
    		 -83.57

    Piotroski F-Score

    n/a
    		 2

    Add to Watchlist